Arrhythmotech, a novel medical device and software platform, received the Innovation of the Year Award during TechPoint’s 18th annual Mira Awards honoring the best of tech in Indiana.
Arrhythmotech’s neuECG(TM) platform is capable of detecting sympathetic nerve signaling (fight-or-flight activity) non-invasively on the skin with greater accuracy than traditional methods.
SKNA is a novel continuous digital biomarker that will have an impact in a number of healthcare, clinical research and wearable technology markets. The patent pending neuECG is the only product capable of detecting SKNA, and Arrhythmotech will be the world leader in technology products that harness this capability.
The practical applications could be revolutionary for clinical indications such as chronic and acute pain, epilepsy, sleep apnea, high blood pressure, sudden cardiac death, atrial fibrillation and others. Arrhythmotech is also exploring wearable and consumer applications like stress detection, human performance, fraud detection, anxiety, fatigue, mindfulness and others.
The Mira Awards judges recognize the tremendous contributions of Dr. Peng-Sheng Chen, his research and discoveries leading to the development of Arrhythmotech’s neuECG(TM) platform. The neuECG device and software have received both a Phase I ($200,000) and Phase II ($1,500,000) STTR grant awards from the National Institute of Health, and Arrhytmotech collaborators at Indiana University, Mayo Clinic and Cedars-Sinai Medical Center carried out the initial prototype testing on neuECG.
In collaboration with Rose-Hulman Ventures, Arrhythmotech has developed a beta version of the neuECG device/software platform. The beta is currently being tested at Indiana University and other top ranked research institutions around the globe. Key thought leaders in various clinical specialties will support Arrhythmotech’s efforts to validate SKNA and neuECG in multiple clinical areas. In 2017, Arrhythmotech will raise a seed round of financing to support further product development and support ongoing business development efforts.